Relationship Between Disease-Modifying Therapy and Depression in Multiple Sclerosis

Kirzinger, S; Jones, Jason P.; Siegwald, Angela

doi:10.7224/1537-2073.2012-036

Cited by 13 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moroeover, many recent studies showed that increased incidence of depression in MS patients is associated with IFNβ therapy [46, 47]. Contrary, Kirzinger et al [48] indicated no differences in mean BDI score in MS patients after over 48 months of disease-modifying therapy. In our study we did not observe any differences in mean BDI scores between pre-treated patients and patients treated with interferons or glatiramer acetate, but there were differences observed between pre-treated and mitoxantrone treated patients.…”

Section: Discussionmentioning

confidence: 99%

Melatonin Acts as Antioxidant and Improves Sleep in MS Patients

et al. 2014

View full text Add to dashboard Cite

The relationship between the prevalence of multiple sclerosis (MS) and sunlight’s ultraviolet radiation was proved. Oxidative stress plays a role in the pathogenic traits of MS. Melatonin possesses antioxidative properties and regulates circadian rhythms. Sleep disturbances in MS patients are common and contribute to daytime fatigue. The aim of study was to evaluate 5 mg daily melatonin supplementation over 90 days on serum total oxidant status (TOS), total antioxidant capacity (TAC) and its influence on sleep quality and depression level of MS patients. A case–control prospective study was performed on 102 MS patients and 20 controls matched for age and sex. The Kurtzke’s Expanded Disability Status Scale, magnetic resonance imaging examinations, Athens Insomnia Scale (AIS), Beck Depression Inventory questionnaires were completed. Serum TOS and TAC levels were measured. We observed higher serum levels of TOS in all MS groups, while after melatonin treatment the TOS levels significantly decreased. The TAC level was significantly lower only in mitoxantrone-treated group and it increased after melatonin supplementation. A strong positive correlation between T1Gd(+) number lesions and TAC level in interferon-beta-1A group was observed. AIS group mean score above 6 defining insomnia were observed in interferon-beta-1B-group, glatiramer acetate-group and mitoxantrone-group: 6.62 ± 2.88, 8.45 ± 2.07, 11.1 ± 3.25, respectively. After melatonin treatment the AIS mean scores decrease in glatiramer acetate-group and mitoxantrone-group achieving 5.25 ± 1.14 and 7.08 ± 2.39, respectively (p < 0.05). Finding from our study suggest that melatonin can act as an antioxidant and improves reduced sleep quality in MS patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Melatonin Acts as Antioxidant and Improves Sleep in MS Patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This finding contrasts with a study showing that interferon or glatiramer acetate treatment has no effect on depression as measured by the BDI. 31 Furthermore, subcutaneous interferon beta-1a was not found to have …”

Section: Mood and Cognitionmentioning

confidence: 98%

Naps-MS

Sater¹,

Gudesblatt²,

Kresa-Reahl³

et al. 2016

International Journal of MS Care

View full text Add to dashboard Cite

Background: Patients with multiple sclerosis (MS) have higher rates of fatigue, mood disturbance, and cognitive impairments than healthy populations. Disease-modifying agents may affect sleep. Although patients taking natalizumab often show improvement in fatigue during the first year of therapy, the mechanism behind this effect is unknown. The aim of the NAPS-MS study was to investigate whether natalizumab affected objective measures of sleep as determined by polysomnography (PSG) and multiple sleep latency testing (MSLT) in patients with MS with fatigue or sleepiness initiating therapy. Additional goals were to evaluate changes in measures of fatigue, mood, and cognition and to correlate these measures with objective sleep measures. Methods: Patients underwent PSG and MSLT before their first natalizumab infusion and after their seventh. Patients completed the Modified Fatigue Impact Scale, Fatigue Severity Scale (FSS), Epworth Sleepiness Scale (ESS), and visual analogue scale for fatigue (VAS-F) at their first, fourth, and seventh natalizumab infusions. NeuroTrax cognitive tests and the Hospital Anxiety and Depression Scale (HADS) were performed at the first and seventh natalizumab infusions. Results: Changes in sleep efficiency, wakefulness after sleep onset, and multiple sleep latency from baseline to 6 months of therapy did not reach significance. The FSS, VAS-F, ESS, and HADS scores were significantly improved after 6 months of therapy; cognitive scores were not significantly improved. Conclusions: Although treatment with natalizumab was associated with improvements in fatigue, sleepiness, and mood, changes in objective measures of sleep were not significant.

show abstract

“…Unfortunately, there is some evidence that IFNB treatment exacerbates depressive symptoms more likely than GA (Pandya and Patten, 2002 ; Goëb et al, 2003 ; Arnett and Randolph, 2006 ), therefore in patients with a history of depression GA treatment is often preferred (Wilken and Sullivan, 2007 ). However, this issue seems not entirely solved, with some studies reporting no differences between IFNB and GA (Kirzinger et al, 2013 ) or no significant beneficial effect of GA on mood-related outcomes (Jongen et al, 2010 ).…”

Section: The Impact Of Ms Drugs On Behavioral Outcomes: the Example Omentioning

confidence: 99%

Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis

Gentile

Vito

Fresegna

et al. 2015

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Microglia is increasingly recognized to play a crucial role in the pathogenesis of psychiatric diseases. In particular, microglia may be the cellular link between inflammation and behavioral alterations: by releasing a number of soluble factors, among which pro-inflammatory cytokines, that can regulate synaptic activity, thereby leading to perturbation of behavior. In multiple sclerosis (MS), the most common neuroinflammatory disorder affecting young adults, microglia activation and dysfunction may account for mood symptoms, like depression and anxiety, that are often diagnosed in patients even in the absence of motor disability. Behavioral studies in experimental autoimmune encephalomyelitis (EAE), the animal model of MS, have shown that emotional changes occur early in the disease and in correlation to inflammatory mediator and neurotransmitter level alterations. However, such studies lack a full and comprehensive analysis of the role played by microglia in EAE-behavioral syndrome. We review the experimental studies addressing behavioral symptoms in EAE, and propose the study of neuron-glia interaction as a powerful but still poorly explored tool to investigate the burden of microglia in mood alterations associated to MS.

show abstract

Relationship Between Disease-Modifying Therapy and Depression in Multiple Sclerosis

Cited by 13 publications

References 26 publications

Melatonin Acts as Antioxidant and Improves Sleep in MS Patients

Melatonin Acts as Antioxidant and Improves Sleep in MS Patients

Naps-MS

Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis

Contact Info

Product

Resources

About